Allergan Plc (AGN)

149.30
NYSE : Health Technology
Prev Close 153.53
Day Low/High 149.17 / 153.36
52 Wk Low/High 125.84 / 197.00
Avg Volume 2.95M
Exchange NYSE
Shares Outstanding 332.61M
Market Cap 51.07B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.89%)
Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

Tech Rotation Hits Market; Bullpen Update

We are looking at today's rotation as an opportunity to pick up a high-quality name at a discount.

Allergan Pushes Back on M&A Questions; Comcast Happy With Its Portfolio - ICYMI

Allergan Pushes Back on M&A Questions; Comcast Happy With Its Portfolio - ICYMI

Botox maker Allergan's CEO is pushing back against activist investors and may get help from the company's latest earnings report.

Hated Stocks May Not Always Stay Hated

Recent moves in industrial stocks demonstrate the importance of buying hated stock/groups when your conviction is high.

Allergan Announces $2 Billion Share Buyback Program, Raises Guidance

Allergan Announces $2 Billion Share Buyback Program, Raises Guidance

The drug giant beat analyst expectations for Q2 and issued positive guidance for the rest of the year.

3 Best Chip Stocks to Own After AMD's Monster Earnings Beat: Market Recon

3 Best Chip Stocks to Own After AMD's Monster Earnings Beat: Market Recon

Micron Technology, Intel and Lam Research are good buys on this heat in semiconductors.

Facebook, Amazon, AMD, Qualcomm and PayPal - 5 Things You Must Know

Facebook, Amazon, AMD, Qualcomm and PayPal - 5 Things You Must Know

U.S. stock futures are mixed as investors react with caution to a broadly worded trade truce between the European Union and the United States; Facebook tanks as the social media giant points to slower growth; AMD swings to a profit; Qualcomm scraps deal for NXP.

It's All About Expectations: Cramer's 'Mad Money' Recap (Tuesday 7/10/18)

It's All About Expectations: Cramer's 'Mad Money' Recap (Tuesday 7/10/18)

Jim Cramer uses PepsiCo's earnings, which crushed analysts' expectations, to illustrate why investors need to do their own homework to find real winners.

Aegon And Santander To Expand Successful Partnership In Spain

Aegon And Santander To Expand Successful Partnership In Spain

Aegon today announces that it has signed an agreement to expand its successful partnership with Banco Santander in Spain.

Big-Game Hunting for My Next 10-Bagger

Big-Game Hunting for My Next 10-Bagger

It's every investor's dream to find a stock that goes up at least 1,000%; here are a few that did.

Aegon Announces Repurchase Of Shares To Neutralize Stock Dividend

Aegon Announces Repurchase Of Shares To Neutralize Stock Dividend

Shareholders were given the opportunity to choose between receiving the 2017 final dividend of EUR 0.

Markets Lower on Tuesday: Don't Lose Sight of the Bigger Picture

We are looking to buy into weakness today, even though the market has gotten significantly tougher over the past few days.

Aegon Provides Update On Financial Transformation And Capital Management

Aegon Provides Update On Financial Transformation And Capital Management

Today, at Aegon's first interactive webinar for analysts and investors, CFO Matt Rider will detail the company's ongoing actions to deliver on its financial transformation, approach to capital management and prioritization in capital deployment.

Is Goldman Sachs Going to Be the Next Allergan?

Is Goldman Sachs Going to Be the Next Allergan?

Don't count on it. The fundamentals paint two very different pictures, Cramer says.

Jim's Daily Rundown

Jim discusses Comcast's offer for Fox, Kohl's, Amazon, 3M, JPMorgan, Goldman Sachs, Citigroup and more!

Stocks Defying Gravity: Cramer's 'Mad Money' Recap (Monday 6/11/18)

Stocks Defying Gravity: Cramer's 'Mad Money' Recap (Monday 6/11/18)

Markets look calm, but we're seeing some extraordinary breakouts, says Jim Cramer.

Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't

Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't

You should be thinking positively these days if your stock has had a run or even if it hasn't as a preponderance of good things is liable to happen.

Last Week's Portfolio Changes

We exited one stock, entered another, raised our price target on Kohl's and downgraded Nordstrom.

Weekly Roundup

Markets bathed in the afterglow of the strong jobs report for most of the week.

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.

Dow Jumps Nearly 100 Points as Nasdaq, S&P 500 Slide

Dow Jumps Nearly 100 Points as Nasdaq, S&P 500 Slide

Stocks finished mixed on Thursday as concerns mount over the potential for a major rift on trade and tariffs when G-7 leaders meet later this week.

Jamie Dimon, Warren Buffett, Allergan and Google - 5 Things You Must Know

Jamie Dimon, Warren Buffett, Allergan and Google - 5 Things You Must Know

U.S. stock futures are higher on Thursday and stocks in Europe and Asia extend gains; Jamie Dimon and Warren Buffett urge companies to consider no longer providing quarterly earnings guidance.

Five Below Tops Expectations and 4 Other Stories to Watch Premarket Thursday

Five Below Tops Expectations and 4 Other Stories to Watch Premarket Thursday

As futures point higher, these are the headlines you need to get up to speed during your morning commute.

Jim Cramer: Tech Can't Do it All Alone

Jim Cramer: Tech Can't Do it All Alone

Tech and retail gains aren't enough to lead markets to new highs.

Jim's Daily Rundown

Jim discusses Constellation Brands, Goldman Sachs and a new position in Salesforce.com.

Jim's Daily Rundown

Jim discusses our decision to exit Allergan, the AAP Bullpen, Apple's upcoming Worldwide Developers Conference and more!

Exiting Allergan

After a lot of patience and disappointment, we are closing our remaining small 'spec' position.

Weekly Roundup

Markets go through a short and volatile week.

Two Antibiotic Plays

Two Antibiotic Plays

They may not get all the attention, but antibiotic drugs are increasingly important.

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

TheStreet Quant Rating: D+ (Sell)